PE20061077A1 - Composicion farmaceutica que comprende 7-terbutoxi-imino-metil-camptotecina - Google Patents

Composicion farmaceutica que comprende 7-terbutoxi-imino-metil-camptotecina

Info

Publication number
PE20061077A1
PE20061077A1 PE2005001353A PE2005001353A PE20061077A1 PE 20061077 A1 PE20061077 A1 PE 20061077A1 PE 2005001353 A PE2005001353 A PE 2005001353A PE 2005001353 A PE2005001353 A PE 2005001353A PE 20061077 A1 PE20061077 A1 PE 20061077A1
Authority
PE
Peru
Prior art keywords
composition
weight
terbutoxi
camptotechin
imino
Prior art date
Application number
PE2005001353A
Other languages
English (en)
Inventor
Isabel Ottinger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35691476&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20061077(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20061077A1 publication Critical patent/PE20061077A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN PRINCIPIO ACTIVO TAL COMO 7-TERBUTOXI-IMINO-METIL-CAMPTOTECINA EN UNA CANTIDAD COMPRENDIDA ENTRE 0.05% A 20% EN PESO DE LA COMPOSICION; B) UN AGENTE LIPOFILICO TALES COMO MONOGLICERIDOS Y DIGLICERIDOS DE ACIDOS GRASOS DE 8 A 10 ATOMOS DE CARBONO, CITRATO DE TRIETILO, ENTRE OTROS; EN UNA CANTIDAD COMPRENDIDA ENTRE 5% A 85% EN PESO DE LA COMPOSICION; C) UN TENSOACTIVO A BASE DE ACEITE DE RICINO HIDROGENADO CON POLIETILENGLICOL EN UNA CANTIDAD COMPRENDIDA ENTRE 5% A 90% EN PESO DE LA COMPOSICION; D) UN COMPONENTE HIDROFILICO TALES COMO PROPILENGLICOL, PEG 400, LACTATO DE ETILO, ENTRE OTROS, EN UNA CANTIDAD COMPRENDIDA ENTRE 5% A 60% EN PESO DE LA COMPOSICION; E) UN COSOLVENTE EN UNA CANTIDAD COMPRENDIDA ENTRE 0 A 20% EN PESO DE LA COMPOSICION Y F) UNO O MAS ADITIVOS TALES COMO ANTIOXIDANTES, AGENTES ANTIMICROBIANOS, ESTABILIZANTES, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCESO DE PREPARACION. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS TAL COMO EL CANCER
PE2005001353A 2004-11-19 2005-11-17 Composicion farmaceutica que comprende 7-terbutoxi-imino-metil-camptotecina PE20061077A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62975704P 2004-11-19 2004-11-19

Publications (1)

Publication Number Publication Date
PE20061077A1 true PE20061077A1 (es) 2006-11-13

Family

ID=35691476

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005001353A PE20061077A1 (es) 2004-11-19 2005-11-17 Composicion farmaceutica que comprende 7-terbutoxi-imino-metil-camptotecina

Country Status (28)

Country Link
US (1) US8518961B2 (es)
EP (1) EP1814520B1 (es)
JP (1) JP4982378B2 (es)
KR (1) KR101283840B1 (es)
CN (1) CN101056619A (es)
AR (1) AR052033A1 (es)
AU (1) AU2005306018B2 (es)
BR (1) BRPI0518448A2 (es)
CA (1) CA2584343C (es)
DK (1) DK1814520T3 (es)
ES (1) ES2572133T3 (es)
GT (1) GT200500310A (es)
HR (1) HRP20160446T1 (es)
HU (1) HUE027135T2 (es)
IL (1) IL182703A (es)
MA (1) MA29076B1 (es)
MX (1) MX2007005897A (es)
MY (1) MY148647A (es)
NO (1) NO342592B1 (es)
NZ (1) NZ554551A (es)
PE (1) PE20061077A1 (es)
PL (1) PL1814520T3 (es)
RU (3) RU2007122470A (es)
SI (1) SI1814520T1 (es)
TN (1) TNSN07193A1 (es)
TW (1) TWI368521B (es)
WO (1) WO2006053755A1 (es)
ZA (1) ZA200703148B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
ITRM20050418A1 (it) * 2005-08-04 2007-02-05 Sigma Tau Ind Farmaceuti Sistemi terapeutici a rilascio immediato per il migliorato assorbimento orale di 7-[(e)-t-butilossimminometil] camptotecina.
TW200800195A (en) * 2005-08-10 2008-01-01 Novartis Ag Organic compounds
EP2077834A2 (en) * 2006-10-31 2009-07-15 Wyeth Formulations of phospholipase enzyme inhibitors
US20100070052A1 (en) * 2008-08-19 2010-03-18 Robb Fujioka System and method for providing applications and peripherals to a fixed price component-based computing platform
CN103313697B (zh) * 2010-06-29 2016-06-01 维瑞斯特姆股份有限公司 激酶抑制剂的口服制剂
AU2011280031B2 (en) 2010-06-30 2015-09-10 Verastem, Inc. Synthesis and use of Kinase inhibitors
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
KR102657097B1 (ko) 2018-12-19 2024-04-15 코어셉트 쎄라퓨틱스 인코포레이티드 헤테로아릴-케톤 융합 아자데칼린 화합물인 렐라코릴란트를 함유하는 약학적 제제
WO2024042523A1 (en) * 2022-08-24 2024-02-29 Lyotropic Delivery Systems Ltd. Oral delivery of active compounds for treating glycogen storage diseases

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9113872D0 (en) 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
CA2151491A1 (en) * 1992-12-24 1994-07-07 Robert J. Kaufman Fluorocarbon emulsions
TW406020B (en) 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5597829A (en) * 1994-05-09 1997-01-28 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of camptothecin and methods for uses thereof
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
PL191780B1 (pl) 1997-07-29 2006-07-31 Upjohn Co Kompozycja farmaceutyczna w postaci samoemulgującej formulacji związków lipofilowych i samoemulgujące podłoże formulacji
AR013261A1 (es) 1997-08-01 2000-12-13 Smithkline Beecham Corp Formulaciones farmaceuticas para analogos de camptotecina en capsula de gelatina
AU3843999A (en) 1998-05-07 1999-11-23 Elan Corporation, Plc Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems
US20030059465A1 (en) 1998-05-11 2003-03-27 Unger Evan C. Stabilized nanoparticle formulations of camptotheca derivatives
GB9903547D0 (en) 1999-02-16 1999-04-07 Novartis Ag Organic compounds
DE69901379T2 (de) * 1999-03-09 2002-11-07 Sigma Tau Ind Farmaceuti Camptothecin-Derivate mit Antitumor-Wirkung
IT1306129B1 (it) 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
EP1185301A1 (en) 1999-05-24 2002-03-13 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
GB9918885D0 (en) 1999-08-10 1999-10-13 Pharmacia & Upjohn Spa Pharmaceutical formulations in hydroxypropymethycellulose capsules
GB9925127D0 (en) 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
US20040009229A1 (en) 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
GB0001928D0 (en) * 2000-01-27 2000-03-22 Novartis Ag Organic compounds
US20020150615A1 (en) 2001-02-12 2002-10-17 Howard Sands Injectable pharmaceutical composition comprising microdroplets of a camptothecin
US6653319B1 (en) 2001-08-10 2003-11-25 University Of Kentucky Research Foundation Pharmaceutical formulation for poorly water soluble camptothecin analogues
CA2461556A1 (en) 2001-10-15 2003-04-24 Crititech, Inc. Compositions and methods for delivery of microparticles of poorly water soluble drugs and methods of treatment
US20060078618A1 (en) 2001-12-11 2006-04-13 Constantinides Panayiotis P Lipid particles and suspensions and uses thereof
JP2003267891A (ja) 2002-03-13 2003-09-25 Mitsubishi-Kagaku Foods Corp Ｗ／ｏ／ｗ型エマルション製剤
CZ294371B6 (cs) 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
EP1393719A1 (en) 2002-08-23 2004-03-03 Munich Biotech AG Camptothecin-carboxylate formulations
JP4426749B2 (ja) 2002-07-11 2010-03-03 株式会社産学連携機構九州 Ｏ／ｗ型エマルション製剤
US20040171560A1 (en) 2002-12-23 2004-09-02 Dabur Research Foundation Stabilized pharmaceutical composition
JP2006199590A (ja) 2003-09-04 2006-08-03 Nano Career Kk 水溶性の塩基性薬物内包ナノ粒子含有組成物
WO2005042539A1 (en) 2003-10-29 2005-05-12 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
EP1706098A4 (en) * 2003-11-26 2012-08-15 Supernus Pharmaceuticals Inc MICELLAR SYSTEMS SUITABLE FOR THE DELIVERY OF LIPOPHILIC OR HYDROPHOBIC COMPOUNDS
WO2005060871A1 (en) 2003-12-17 2005-07-07 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of camptothecins and process for making same
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos

Also Published As

Publication number Publication date
AU2005306018A1 (en) 2006-05-26
KR20070084357A (ko) 2007-08-24
CA2584343A1 (en) 2006-05-26
TWI368521B (en) 2012-07-21
NZ554551A (en) 2010-01-29
WO2006053755A1 (en) 2006-05-26
AU2005306018B2 (en) 2009-12-17
MX2007005897A (es) 2007-06-19
IL182703A0 (en) 2007-09-20
BRPI0518448A2 (pt) 2008-11-18
TNSN07193A1 (en) 2008-11-21
HRP20160446T1 (hr) 2016-05-20
IL182703A (en) 2015-11-30
JP2008520606A (ja) 2008-06-19
KR101283840B1 (ko) 2013-07-15
ZA200703148B (en) 2008-09-25
ES2572133T3 (es) 2016-05-30
US20080125450A1 (en) 2008-05-29
CA2584343C (en) 2013-09-24
MY148647A (en) 2013-05-15
MA29076B1 (fr) 2007-12-03
NO20072258L (no) 2007-08-10
EP1814520B1 (en) 2016-04-13
PL1814520T3 (pl) 2016-08-31
AR052033A1 (es) 2007-02-28
RU2015131700A (ru) 2017-02-02
TW200631606A (en) 2006-09-16
RU2012120388A (ru) 2013-11-27
CN101056619A (zh) 2007-10-17
SI1814520T1 (sl) 2016-06-30
RU2620331C2 (ru) 2017-05-24
GT200500310A (es) 2006-06-19
NO342592B1 (no) 2018-06-18
EP1814520A1 (en) 2007-08-08
RU2007122470A (ru) 2008-12-27
DK1814520T3 (en) 2016-05-30
US8518961B2 (en) 2013-08-27
HUE027135T2 (en) 2016-08-29
JP4982378B2 (ja) 2012-07-25

Similar Documents

Publication Publication Date Title
PE20061077A1 (es) Composicion farmaceutica que comprende 7-terbutoxi-imino-metil-camptotecina
ES2524320T3 (es) Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo
CY1120888T1 (el) Διαδερμικες φαρμακευτικες συνθεσεις περιλαμβανοντας ενεργους παραγοντες
PE20060464A1 (es) Composicion farmaceutica que comprende flibanserina para el tratamiento de trastornos sexuales
AR052545A1 (es) Suspension no acuosa inyectable
AR073123A1 (es) Composicion farmaceutica que comprende un taxano sustancialmente amorfo para utilizarse en el tratamiento de la enfermedad neoplasica
SV2008003071A (es) Composiciones farmaceuticas de antagonistas del anticuerpo anti-cd40
HRP20220361T1 (hr) Postupak i sastav za liječenje očne hipertenzije i glaukoma
PE20130216A1 (es) Formulacion topica para un inhibidor de jak
AR077126A1 (es) Composiciones farmaceuticas acuosas que contienen complejos de borato-poliol
GT201200024A (es) Formulación subcutánea de anticuerpo anti-her2
PE20120322A1 (es) Composicion farmaceutica que comprende faldaprevir o una sal del mismo en un vehiculo auto-emulsionante
PE20151425A1 (es) Formulaciones farmaceuticas muy concentradas que comprenden un anticuerpo anti-cd20
PE20141297A1 (es) Formulaciones peptidicas robustas de liberacion controlada
HUP0301405A2 (hu) Fokozott oldékonyságú gyógyhatású komponenseket tartalmazó készítmények
CO6311006A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+ efectiva a dosis altas
CO2021000174A2 (es) Composiciones tópicas para el alivio del dolor
EA201170413A1 (ru) Составы с замедленным высвобождением, полученные с применением неводных носителей
AR055591A1 (es) Una composicion topica protectora de la piel y su uso
BR112015020707A2 (pt) formulações transdermicas
EA200701750A1 (ru) Улучшенные составы фенофибрата, содержащие ментол или пэг/полоксамер
BRPI0418070A (pt) composição para cuidados pessoais, uso de uma uréia substituìda e método para reduzir a degradação da cor de uma composição para cuidados pessoais
PE20090387A1 (es) Formulacion de pasireotida
ES2614481T3 (es) Composición para la administración de principios activos mediante dispositivos de implante
AR061269A1 (es) Composicion y metodo de revascularizacion para el tratamiento de enfermedades isquemicas usando eritropoyetina

Legal Events

Date Code Title Description
FC Refusal
FG Grant, registration
FD Application declared void or lapsed